Duan X, Xia L, Zhang Z, Ren Y, Pomper MG, Rowe SP, Li X, Li N, Zhang N, Zhu H, Yang Z*, Sheng X*, Yang X*. First-in-human study of the radioligand 68Ga-N188 targeting nectin-4 for PET/CT imaging of advanced urothelial carcinoma.,Clin Cancer Res,2023 Apr 24;CCR-23-0609.

Zhou L#, Shao Z#, Liu Y, Yan X, Li J, Wu X, Tang B, Li S, Cui C, Chi Z, Si L, Kong Y, Mao L, Lian B, Wang X, Bai X, Dai J, Guo J, Sheng X*. HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population.,Oncologist,2023 Mar 27:oyad070.

Huizi Lei, Yun Ling, Pei Yuan, Xieqiao Yan, Lin Wang, Yanxia Shi, Xin Yao, Hong Luo, Benkang Shi, Jiyan Liu, Zhisong He, Guohua Yu, Weiqing Han, Changlu Hu, Zhihong Chi, Chuanliang Cui, Lu Si, Jianmin Fang, Jun Guo, Xinan Sheng*, Aiping Zhou*, Jianming Ying*.Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer.,Journal of the National Cancer Center,2023;3(2), 121-128

Sheng X*, Ye D, Zhou A, Yao X, Luo H, He Z, Wang Z, Zhao Y, Ji Z, Zou Q, He C, Guo J, Tu X, Liu Z, Shi B, Liu B, Chen P, Wei Q, Hu Z, Zhang Y, Jiang K, Zhou F, Wu D, Fu C, Li X, Wu B, Wang L, Qin S, Li G, Liu Y, Guo H, Chen K, Zhang D, Wang G, Ding L, Wang Y, Yuan X, Guo J*. Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT),Eur J Cancer,2023 Jan;178:205-215.

Zhou L#, Liu Y#, Mo J, Cui C, Chi Z, Si L, Kong Y, Yan X, Li S, Wu X, Li J, Xu H, Cao D, Guo J, Sheng X*. Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma.,Urol Oncol,2022 Aug;40(8):385.e1-385.e8.

Yan X, Zhou L, Li S, Wu X, Cui C, Chi Z, Si L, Kong Y, Tang B, Li C, Mao L, Wang X, Lian B, Bai X, Dai J, Guo J, Sheng X*. Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma.,Clin Genitourin Cancer,2022 Aug;20(4):354-362

Li S, Wu X, Yan X, Zhou L, Chi Z, Si L, Cui C, Tang B, Mao L, Lian B, Wang X, Bai X, Dai J, Kong Y, Tang X, Feng H, Yao S, Flaherty KT, Guo J*, Sheng X*. Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis.,J Immunother Cancer,10(2):e004036

Sheng X#, Chen H#, Hu B, Yao X, Liu Z, Yao X, Guo H, Hu Y, Ji Z, Luo H, Shi B, Liu J, Wu J, Zhou F, He Z, Fan J, Wang W, Feng H, Yao S, Keegan P, Huang Y, Guo J*. Safety, Efficacy and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03,Clin Cancer Res,28(3):489-497

Tang B#, Mo J#, Yan X, Duan R, Chi Z, Cui C, Si L, Kong Y, Mao L, Li S, Zhou L, Lian B, Wang X, Bai X, Xu H, Li C, Dai J, Guo J*, Sheng X*. Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma.,Eur J Cancer,156:83-92.

Tang B, Mo J, Yan X, Duan R, Chi Z, Cui C, Si L, Kong Y, Mao L, Li S, Zhou L, Lian B, Wang X, Bai X, Xu H, Li C, Dai J, Guo J*, Sheng X*. Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma.,Eur J Cancer.,2021 Aug 20; 156:83-92.

Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G, Ying J, Han W, Hu C, Ling Y, Chi Z, Cui C, Si L, Fang J, Zhou A*, Guo J*. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.,Clin Cancer Res,2021 Jan 1;27(1):43-51.

Wang S, Zhu H, Ding J, Wang F, Meng X, Ding L, Zhang Y, Li N, Yao S, Sheng X*, Yang Z*. Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab: A Pilot Clinical Translation Study. Clin Nucl Med.,Clin Nucl Med,2021 May 1;46(5):382-388.

Yan X#, Sheng X#, Chi Z, Si L, Cui C, Kong Y, Tang B, Mao L, Wang X, Lian B, Li S, Bai X, Zhou L, Dai J, Yao H, Guo J*. Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma.,J Clin Oncol,2021,39(8):881-889

Li X#, Li S#, Chi Z, Cui C, Si L, Yan X, Mao L, Lian B, Tang B, Wang X, Bai X, Zhou L, Kong Y, Dai J, Guo J, Sheng X*. Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma.,Urol Oncol,2020 Jul 9:S1078-1439(20)30277-5.

Huang H, Zhu H, Xie Q, Tian X, Yang X, Feng F, Jiang Q, Sheng X*, Yang Z*. Evaluation of 124I-JS001 for hPD1 immuno-PET imaging using sarcoma cell homografts in humanized mice.,Acta Pharm Sin B,2020;10(7):1321-1330

Sheng X, Jin J, He Z, Huang Y, Zhou A, Wang J, Ren X, Ye D, Zhang X, Qin S, Zhou F, Wang B, Guo J. Pazopanib Versus Sunitinib in Chinese Patients With Locally Advanced or Metastatic Renal Cell Carcinoma: Pooled Subgroup Analysis From the Randomized, COMPARZ Studies,BMC Cancer,2020 Mar 14;20(1):219

Sheng X#, Yan X#, Chi Z, Cui C, Si L, Tang B, Li S, Mao L, Lian B, Wang X, Bai X, Zhou L, Kong Y, Dai J, Ding L, Mao L, Guo J*. Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma.,EBioMedicine,2020 May;55:102755

Sheng X, Yan X, Chi Z, Si L, Cui C, Tang B, Li S, Mao L, Lian B, Wang X, Bai X, Zhou L, Kong Y, Dai J, Wang K, Tang X, Zhou H, Wu H, Feng H, Yao S, Flaherty KT, Guo J*. Axitinib in combination with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with metastatic mucosal melanoma: a non-randomized, open-label, dose-finding, and cohort-expansion phase 1b trial.,Journal of Clinical Oncology,2019 Nov 10;37(32):2987-2999.

Guo X, Zhu H, Liu T, Xu X, Kong Y, Yao S, Sheng X*, Yang Z*. Development of 99m Tc-conjugated JS001 Antibody for in Vivo Mapping of PD-1 Distribution in Murine,Bioorg Med Chem Lett,2019 Aug 15;29(16):2178-2181

肿瘤生物治疗学, 参编, 人民卫生出版社, 2021.5

晚期泌尿肿瘤的临床与转化医学研究

粘膜黑色素瘤综合治疗

以PD-L1为生物标记物的晚期上尿路尿路上皮癌的免疫治疗研究, 课题负责人, 2016.6.7～2019.6.7, 北京市科委首都临床特色应用研究/Z161100000516062

HER2阳性尿路上皮癌抗体偶联药物继发性耐药的机制及逆转耐药的干预研究, 课题负责人, 2022.1.1～2025.12.31, 国 家自然科学基金委员会

基于基因表达谱分析的阿昔替尼联合PD-1 单抗治疗转移性肾癌疗效预测模型的构建, 课题负责人, 2023.1.1～2025.12.1, 北京市希思科临床肿瘤学研究基金会

研究生招生计划

招生年度	招生专业	学位级别	学位类型	研究方向	选拔方式	操作
2024	肿瘤内科学	博士	专业学位	临床技能训练与研究	申请考核制
2024	肿瘤内科学	长学制	专业学位	临床技能训练与研究	长学制二级学科培养
2024	肿瘤内科学	硕士	专业学位	临床技能训练与研究	全国统考